DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Bromocriptine - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antiparkinson Agents
  • Antidyskinetics

Dosage Forms

  • Capsule

Brands / Synonyms

Alti-Bromocriptine; Apo-Bromocriptine; Bromergocryptine; Bromocriptin; Bromocriptina [Inn-Spanish]; Bromocriptine; Bromocriptine Mesylate; Bromocriptine Methanesulfonate; Bromocriptine [Usan:Ban:Inn]; Bromocriptinum [Inn-Latin]; Bromocryptine; Bromocryptine Mesylate; Bromoergocriptine; Bromoergocryptine; Parlodel; Parlodel Snaptabs


For treatment of idiopathic or postencephalitic Parkinson's disease, dysfunctions associated with hyperprolactinemia and in the treatment of acromegaly.


Bromocriptine is an ergoline derivitave dopamine agonist that is used in the treatment of amenorrhea, female infertility, abnormal discharge of breast milk, hypogonadism, Parkinson's disease, and acromegaly. Bromocriptine produces its therapeutic effect in the treatment of Parkinson's disease, a clinical condition characterized by a progressive deficiency in dopamine synthesis in the substantia nigra, by directly stimulating the dopamine receptors in the corpus striatum.

Mechanism of Action

Bromocriptine acts by directly stimulating the dopamine receptors in the corpus striatum.


Not Available


Not Available

Biotrnasformation / Drug Metabolism

Not Available


Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia bromocriptine mesylate should be withdrawn when pregnancy is diagnosed. In the event that bromocriptine mesylate is reinstituted to control a rapidly expanding macroadenoma and a patient experiences a hypertensive disorder of pregnancy, the benefit of continuing bromocriptine mesylate must be weighed against the possible risk of its use during a hypertensive disorder of pregnancy. When bromocriptine mesylate is being used to treat acromegaly, prolactinoma, or Parkinsonís disease in patients who subsequently become pregnant, a decision should be made as to whether the therapy continues to be medically necessary or can be withdrawn. If it is continued, the drug should be withdrawn in those who may experience hypertensive disorders of pregnancy (including eclampsia, preeclampsia, or pregnancy-induced hypertension) unless withdrawal of bromocriptine mesylate is considered to be medically contraindicated. The drug should not be used during the post-partum period in women with a history of coronary artery disease and other severe cardiovascular conditions unless withdrawal is considered medically contraindicated. If the drug is used in the post-partum period the patient should be observed with caution.

Drug Interactions

The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate. Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017